Current EPRI alpha guidance (rev 2 2013) recommends a WBC when alpha CEDE is >10 mrem.
Jack McCarthy, CHP DTO - Decommissioning Health Physics Oyster Creek / Exelon Corporation 609-971-4764 From: Mathiasen, Glenn D. [mailto:[email protected]] Sent: Thursday, April 27, 2017 6:04 PM To: Cady, Jeffrey James:(GenCo-Nuc); Sorber, Bob; [email protected] Subject: [powernet] RE: Basis for WBC after exposure to 1 DAC? The Area Action Level Matrix in the previous revision of the EPRI Alpha Monitoring Guidelines (Dec 2009) included a recommendation for WBC after exposure to >1 DAC alpha or >4 DAC-Hr alpha. (after applying APF). From: Cady, Jeffrey James:(GenCo-Nuc) [mailto:[email protected]] Sent: Thursday, April 27, 2017 2:54 PM To: Sorber, Bob; [email protected]<mailto:[email protected]> Subject: [powernet] RE: Basis for WBC after exposure to 1 DAC? The closest requirement I am aware of is ANI which states a whole body count should be performed if an individual is exposed to airborne concentrations >1DAC alpha or an intake of >4 DAC-hours (alpha-beta-gamma) per seven consecutive days. Jeffrey J. Cady, CHP Radiation Protection Manager Exelon Generation - Braidwood Generating Station 35100 South Route 53 Braceville, IL 60407-9619 Office: 815-417-2700│Cell: 208-360-9480 Email: [email protected]<mailto:[email protected]> From: Sorber, Bob [mailto:[email protected]] Sent: Thursday, April 27, 2017 2:33 PM To: [email protected]<mailto:[email protected]> Subject: [EXTERNAL] [powernet] Basis for WBC after exposure to 1 DAC? RPs, I'm trying to track down the basis of a requirement in our procedures that we perform a whole body count (WBC) following work in an airborne area greater than 1 DAC (after taking account of any respiratory protection factor). This is regardless of the time spent at that concentration. Does anyone know of the basis for this requirement? Thanks in advance. Bob Sorber Corporate Radiation Protection 704-382-7259 [email protected]<mailto:[email protected]> This Email message and any attachment may contain information that is proprietary, legally privileged, confidential and/or subject to copyright belonging to Exelon Corporation or its affiliates ("Exelon"). This Email is intended solely for the use of the person(s) to which it is addressed. If you are not an intended recipient, or the employee or agent responsible for delivery of this Email to the intended recipient(s), you are hereby notified that any dissemination, distribution or copying of this Email is strictly prohibited. If you have received this message in error, please immediately notify the sender and permanently delete this Email and any copies. Exelon policies expressly prohibit employees from making defamatory or offensive statements and infringing any copyright or any other legal right by Email communication. Exelon will not accept any liability in respect of such communications. -EXCIP
